Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Michael FralickSebastian SchneeweissDonald A RedelmeierFahad RazakTara GomesElisabetta PatornoPublished in: Diabetes, obesity & metabolism (2021)
We observed a numerically lower rate of short-/mid-term cardiovascular events for patients newly prescribed an SGLT2 inhibitor compared to metformin, albeit with wide CIs that include the possibility of a null effect. SGLT2 inhibitors were associated with a higher rate of genital infection and diabetic ketoacidosis. Larger cohort studies and long-term clinical trials powered to assess cardiovascular events are necessary to understand the risk-benefit profile of SGLT2 inhibitors as first-line therapy for adults with type 2 diabetes mellitus.
Keyphrases
- cardiovascular events
- coronary artery disease
- cardiovascular disease
- clinical trial
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- type diabetes
- palliative care
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- big data
- pain management
- phase ii
- study protocol
- affordable care act
- patient reported